JP2019521989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521989A5 JP2019521989A5 JP2018565844A JP2018565844A JP2019521989A5 JP 2019521989 A5 JP2019521989 A5 JP 2019521989A5 JP 2018565844 A JP2018565844 A JP 2018565844A JP 2018565844 A JP2018565844 A JP 2018565844A JP 2019521989 A5 JP2019521989 A5 JP 2019521989A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- use according
- administration
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021197648A JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
| JP2023173614A JP7606245B2 (ja) | 2016-06-16 | 2023-10-05 | 眼性新血管形成を低減するための組成物および方法 |
| JP2024213242A JP2025038012A (ja) | 2016-06-16 | 2024-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351231P | 2016-06-16 | 2016-06-16 | |
| US62/351,231 | 2016-06-16 | ||
| PCT/US2017/038012 WO2017218981A2 (en) | 2016-06-16 | 2017-06-16 | Compositions and methods for reducing ocular neovascularization |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197648A Division JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521989A JP2019521989A (ja) | 2019-08-08 |
| JP2019521989A5 true JP2019521989A5 (enExample) | 2020-05-28 |
| JP6990667B2 JP6990667B2 (ja) | 2022-02-03 |
Family
ID=60664289
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565844A Active JP6990667B2 (ja) | 2016-06-16 | 2017-06-16 | 眼性新血管形成を低減するための組成物および方法 |
| JP2021197648A Active JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
| JP2023173614A Active JP7606245B2 (ja) | 2016-06-16 | 2023-10-05 | 眼性新血管形成を低減するための組成物および方法 |
| JP2024213242A Pending JP2025038012A (ja) | 2016-06-16 | 2024-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197648A Active JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
| JP2023173614A Active JP7606245B2 (ja) | 2016-06-16 | 2023-10-05 | 眼性新血管形成を低減するための組成物および方法 |
| JP2024213242A Pending JP2025038012A (ja) | 2016-06-16 | 2024-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20190100582A1 (enExample) |
| EP (4) | EP4674483A3 (enExample) |
| JP (4) | JP6990667B2 (enExample) |
| KR (2) | KR20190038536A (enExample) |
| AU (2) | AU2017286680B2 (enExample) |
| CA (1) | CA3027740A1 (enExample) |
| CY (1) | CY1125152T1 (enExample) |
| DK (1) | DK3472317T3 (enExample) |
| ES (2) | ES2987337T3 (enExample) |
| HR (1) | HRP20220612T1 (enExample) |
| HU (1) | HUE059424T2 (enExample) |
| LT (1) | LT3472317T (enExample) |
| PL (1) | PL3472317T3 (enExample) |
| PT (1) | PT3472317T (enExample) |
| RS (1) | RS63282B1 (enExample) |
| SG (1) | SG11201811230RA (enExample) |
| SI (1) | SI3472317T1 (enExample) |
| SM (1) | SMT202200251T1 (enExample) |
| WO (1) | WO2017218981A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3800191B1 (en) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| JP7095994B2 (ja) | 2015-03-02 | 2022-07-05 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法 |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| EP4653536A3 (en) | 2017-03-17 | 2026-02-25 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| WO2019189643A1 (ja) * | 2018-03-30 | 2019-10-03 | 国立大学法人東京大学 | 腫脹発生抑制型腫瘍溶解性ウイルス |
| TW202106708A (zh) * | 2019-04-24 | 2021-02-16 | 美商銳進科斯生物股份有限公司 | 全人類轉譯後修飾之抗體治療劑 |
| MA54325A (fr) | 2019-06-05 | 2022-05-11 | Regeneron Pharma | Dispositifs et procédés pour l'administration précise de doses |
| WO2021046245A1 (en) * | 2019-09-04 | 2021-03-11 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
| WO2021050094A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| CN114390928A (zh) * | 2019-09-11 | 2022-04-22 | 阿德夫拉姆生物技术股份有限公司 | 使用编码阿柏西普的aav2变体治疗眼新血管疾病的方法 |
| CN114728049A (zh) * | 2019-10-07 | 2022-07-08 | 再生生物股份有限公司 | 腺相关病毒载体药物组合物和方法 |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021108530A1 (en) * | 2019-11-26 | 2021-06-03 | University Of Massachusetts | Recombinant adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
| WO2021163451A1 (en) * | 2020-02-14 | 2021-08-19 | Asklepios Biopharmaceutical, Inc. | Method of treating gene therapy associated toxicity with antibiotics |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN115869425B (zh) * | 2022-12-12 | 2024-08-20 | 北京生物制品研究所有限责任公司 | 一种aav眼用注射液及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994021679A1 (en) | 1993-03-25 | 1994-09-29 | Merck & Co., Inc. | Inhibitor of vascular endothelial cell growth factor |
| US9192685B2 (en) * | 2008-10-07 | 2015-11-24 | Bracco Suisse S.A. | Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same |
| US8663624B2 (en) * | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| CN107012171B (zh) * | 2011-04-22 | 2021-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| EP3800191B1 (en) * | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| EP3570895A1 (en) * | 2017-01-17 | 2019-11-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of expressing a polynucleotide of interest in the cone photoreceptors |
-
2017
- 2017-06-16 DK DK17814228.7T patent/DK3472317T3/da active
- 2017-06-16 SI SI201731153T patent/SI3472317T1/sl unknown
- 2017-06-16 HU HUE17814228A patent/HUE059424T2/hu unknown
- 2017-06-16 RS RS20220484A patent/RS63282B1/sr unknown
- 2017-06-16 LT LTEPPCT/US2017/038012T patent/LT3472317T/lt unknown
- 2017-06-16 EP EP25208689.7A patent/EP4674483A3/en active Pending
- 2017-06-16 KR KR1020197001022A patent/KR20190038536A/ko not_active Abandoned
- 2017-06-16 JP JP2018565844A patent/JP6990667B2/ja active Active
- 2017-06-16 CA CA3027740A patent/CA3027740A1/en active Pending
- 2017-06-16 SG SG11201811230RA patent/SG11201811230RA/en unknown
- 2017-06-16 ES ES22154859T patent/ES2987337T3/es active Active
- 2017-06-16 HR HRP20220612TT patent/HRP20220612T1/hr unknown
- 2017-06-16 EP EP24184081.8A patent/EP4427808B1/en active Active
- 2017-06-16 SM SM20220251T patent/SMT202200251T1/it unknown
- 2017-06-16 PT PT178142287T patent/PT3472317T/pt unknown
- 2017-06-16 KR KR1020227041433A patent/KR102622823B1/ko active Active
- 2017-06-16 EP EP17814228.7A patent/EP3472317B1/en active Active
- 2017-06-16 AU AU2017286680A patent/AU2017286680B2/en active Active
- 2017-06-16 ES ES17814228T patent/ES2916344T3/es active Active
- 2017-06-16 EP EP22154859.7A patent/EP4083203B1/en active Active
- 2017-06-16 WO PCT/US2017/038012 patent/WO2017218981A2/en not_active Ceased
- 2017-06-16 PL PL17814228.7T patent/PL3472317T3/pl unknown
-
2018
- 2018-12-12 US US16/218,350 patent/US20190100582A1/en not_active Abandoned
-
2021
- 2021-12-06 JP JP2021197648A patent/JP7384447B2/ja active Active
-
2022
- 2022-05-12 CY CY20221100331T patent/CY1125152T1/el unknown
- 2022-10-12 US US18/046,112 patent/US20230322911A1/en active Pending
-
2023
- 2023-04-13 AU AU2023202277A patent/AU2023202277B2/en active Active
- 2023-10-05 JP JP2023173614A patent/JP7606245B2/ja active Active
-
2024
- 2024-12-06 JP JP2024213242A patent/JP2025038012A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521990A5 (enExample) | ||
| JP7111924B2 (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| AU2021225178B2 (en) | Treatment of AMD using AAV2 variant with aflibercept | |
| HRP20220612T1 (hr) | Sastavi i metode za smanjenje očne neovaskularizacije | |
| JP2024016207A (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| JP2021503914A5 (enExample) | ||
| JP2018517773A (ja) | ＩｇＧＦｃドメインを有する融合タンパク質の安定な液状製剤 | |
| EP3215123A1 (en) | Methods for treating ocular diseases | |
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| JP2024519629A5 (enExample) | ||
| US20120070428A1 (en) | Treatment of vascularized pigment epithelial detachment with anti-vegf therapy | |
| CN116710137A (zh) | 用于在治疗眼部疾病的方法中使用的vegf拮抗剂 | |
| WO2023236964A1 (zh) | 腺相关病毒药物组合物及其用途 | |
| Zeng et al. | “Para-retinal” vector administration into the deep vitreous enhances retinal transgene expression | |
| TW202508610A (zh) | 醫藥組成物及其用途 | |
| Mellen et al. | Gene therapy for neovascular macular degeneration, diabetic retinopathy, and diabetic macular edema | |
| NZ749897B2 (en) | Treatment of amd using aav2 variant with aflibercept | |
| NZ749897A (en) | Treatment of amd using aav2 variant with aflibercept | |
| Dagueta et al. | Evolving knowledge in pharmacologic treatments of age-related macular degeneration | |
| Fenner et al. | When to change course: timing of treatment change in the management of diabetic macular edema | |
| Schwartz et al. | Progressive release of vitreomacular traction with aflibercept | |
| NZ765038A (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis | |
| Rafieetary et al. | Gene therapy delivery: Examining the evidence | |
| Rusakevich et al. | Gene therapy for nAMD: The current frontier | |
| NZ765038B2 (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |